Main Industry
Health Care
Main Product/Service
EG BioMed offers a suite of blood-based cancer detection tests based on cfDNA methylation analysis. By evaluating methylation markers in specific genes associated with cancers — such as breast, colon, and pancreatic cancer — their assays provide early det
Founded Year
2022
Unified Business No.
90190353
Status
Active
Number of Employees
0
Total Paid-in
Capital
230,300,000 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person. Please do not contact this platform for company inquiries.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
EG BioMed focuses on leveraging DNA methylation technology to develop non‑invasive blood tests for early cancer detection, prognosis monitoring, and recurrence surveillance. With a precision‑medicine approach, they aim to make cancer screening more access